Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Take a brief audio tour around Scrip's Five Must-Know Things, this time for the business week ended 16 October 2020.
In this edition we take a look at progress and setbacks with coronavirus vaccines, a major deal in liver disease, one company's plans in immunology, and prospects for the global oncology market.
These and other Informa Pharma Intelligence podcasts are available on SoundCloud and Apple Podcasts.
Stories mentioned in this episode:
(Also see "Pfizer’s First COVID-19 Vaccine Results Might Be Just Days Away - But Patience Could Pay Off" - Scrip, 14 Oct, 2020.)
(Also see "J&J Says It's Wait And See On COVID-19 Vaccine Delay, Outlines Rosier Outlook for 2021" - Scrip, 13 Oct, 2020.)
(Also see "$1bn Deal Boosts Takeda, Arrowhead’s Liver Disease And RNAi Ambitions" - Scrip, 9 Oct, 2020.)
(Also see "BMS Sees Zeposia As Safer Oral Option In Ulcerative Colitis" - Scrip, 12 Oct, 2020.)
(Also see "R&D Trends Driving Broad Change In Surging Oncology Sector" - Scrip, 9 Oct, 2020.)